Galena Biopharma is a company developing innovative, targeted oncology treatments that address major unmet medical needs in the advancement of cancer care. The NeuVax drug is enrolling its Phase III trial currently and its Abstral drug is proceeding into commercialization this year.
The company reported today the addition of William L. Ashton to its Board of Directors. He is a senior executive with more than 28 years’ experience in biotechnology and pharmaceutical leadership and management. Most recently, at Amgen (Nasdaq: AMGN), he served as vice-president of corporate and government affairs as well as vice-president of sales. Ashton was directly responsible for product launches and dealing with government agencies such as Medicare and Medicaid.
After leaving Amgen, Ashton joined the University of the Sciences in Philadelphia where he serves as Associate Provost and senior vice-president of strategic business development, Founding Dean, Mayes College of Healthcare Business and Policy, and Assistant Professor of Pharmaceutical Business. He is also on the boards of the National Osteoporosis Foundation, Friends of the National Library of Medicine and Sucampo Pharmaceuticals. Ashton is also a commissioner for the Medical Representatives National Certificate Commission.
Galena Biopharma is excited to have him aboard. The company’s president and CEO, Mark J. Ahn, Ph.D., said, “Bill brings an enormous wealth of commercial experience and expertise in pharmaceutical sales, leadership and corporate affairs. . .we look forward to his contributions and guidance in establishing Abstral as the best in class leader in breakthrough cancer pain, as well as preparing for NeuVax commercialization.”